公开(公告)号：US3318771A

公开(公告)日：1967-05-09

申请号：US32733963

申请日：1963-12-02

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： JOHANNES JENSEN VILLY

IPC: C12N9/68

CPC classification number: C12N9/6435 ,  C12Y304/21007

公开(公告)号：US3315802A

公开(公告)日：1967-04-25

申请号：US50175265

申请日：1965-10-22

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： RONNOW LONHOLDT HANS CHRISTIAN ,  HENRIK BJARNO KNUD MARO

IPC: A61B17/06 ,  A61B50/30 ,  A61M25/00

CPC classification number: A61M25/002 ,  A61B17/06133 ,  A61B50/30

公开(公告)号：US2920014A

公开(公告)日：1960-01-05

申请号：US69261257

申请日：1957-10-28

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： KARL PETERSEN ,  JORGEN SCHLICHTKRULL

IPC: A61K38/00 ,  B01D9/00 ,  C07K14/62 ,  C07K14/625

CPC classification number: B01D9/005 ,  A61K38/00 ,  C07K14/62 ,  C07K14/625

公开(公告)号：US2882902A

公开(公告)日：1959-04-21

申请号：US57285656

申请日：1956-03-21

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： OLAV JUNCHER HENNING

IPC: A61M5/28

CPC classification number: A61M5/282

公开(公告)号：US2803583A

公开(公告)日：1957-08-20

申请号：US38638853

申请日：1953-10-15

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： KARL PETERSEN ,  HANS JACOBSEN

IPC: A61K31/43

CPC classification number: A61K31/43

公开(公告)号：US2626228A

公开(公告)日：1953-01-20

申请号：US76527147

申请日：1947-07-31

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： KARL PETERSEN

IPC: C07K14/62

CPC classification number: C07K14/62

公开(公告)号：US2571126A

公开(公告)日：1951-10-16

申请号：US70524846

申请日：1946-10-23

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： EMIL FREDERIKSEN SVEND

IPC: C12N9/94

CPC classification number: C12N9/94 ,  Y10S435/816

公开(公告)号：US3907676A

公开(公告)日：1975-09-23

申请号：US36034073

申请日：1973-05-14

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： JORGENSEN KLAVS HOLGER

IPC: C07K14/625 ,  B01D15/08 ,  C07C103/52 ,  C07G7/00

CPC classification number: C07K14/625

Abstract: The present invention relates to a process of reducing the antigenicity of insulin recovered from pancreas glands of domestic mammals, particularly pork and bovine pancreas glands, and containing antigenic insulin-like substances with a molecular weight about 6,000 together with some antigenic proteins of pancreatic origin with a molecular weight above 6,000. The reduction in antigenicity is obtained by subjecting the insulin to column chromatography on an anion exchanger which is preferably strongly basic while using a water-containing monohydric aliphatic alcohol as eluent, and collecting the eluate fractions containing insulin free or essentially free of the impurities referred to. The purified insulin may be used in all kinds of insulin preparations for clinical use.

Abstract translation: 本发明涉及一种降低从家畜哺乳动物，特别是猪和牛胰腺胰腺回收的胰岛素的抗原性的方法，并且含有分子量约为6,000的抗原性胰岛素样物质​​以及胰腺起源的一些抗原蛋白， 分子量高于6000。 抗原性的降低是通过在使用含水一元脂肪醇作为洗脱液的阴离子交换剂上进行柱层析，优选强碱性的，并收集含有不含或不含有所谓杂质的胰岛素的洗脱液级分 。 纯化的胰岛素可用于各种用于临床用途的胰岛素制剂。

公开(公告)号：US3804861A

公开(公告)日：1974-04-16

申请号：US31181172

申请日：1972-12-04

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： CHRISTENSEN H ,  LUNDT B ,  GRONVALD F ,  ANDERSEN W

IPC: A61K31/64 ,  C07D307/79 ,  C07D311/58 ,  C07D7/32

CPC classification number: C07D307/79 ,  A61K31/64 ,  C07D311/58

Abstract: THE INVENTION PROCESS NOVEL CHROMAN-8-CARBOXYLIC ACIDS OF THE FORMULA:

6-R,8-(HOOC-)CHROMAN

IN WHICH R IS BROMINE, CHLORINE, METHYL OR METHOXY. THESE CARBOXYLIC ACIDS ARE USEFUL AS INTERMEDIATES IN THE PRODUCTION OF PHYSIOLOGICALLY ACTIVE COMPOUNDS. THEY ARE PARTICULARLY USEFUL IN THE PRODUCTION OF ANTIDIABETIC BENZENESULFONYLUREA AND BEBZENESULFONYLSEMICARBAZIDE DERIVATIVES.

公开(公告)号：US3803176A

公开(公告)日：1974-04-09

申请号：US31181272

申请日：1972-12-04

Applicant: NOVO TERAPEUTISK LABOR AS

Inventor： CHRISTENSEN H ,  ANDERSEN W ,  LUNDT B ,  GRONVALD F

IPC: A61K31/64 ,  C07D307/79 ,  C07D311/58 ,  C07D7/32

CPC classification number: A61K31/64 ,  C07D307/79 ,  C07D311/58 ,  Y10S514/866

Abstract: THE INVENTION PROVIDES NOVEL SULFONYLUREA DERIVATIVES OF THE FORMULA:

3-R4,4-R3,6-R2,8-((4-(R1-NH-CO-NH-SO2-)PHENYL)-CH2-CH2-NH-

CO-)-3,4-DIHYDRO-2H-CHROMENE

AND SALTS THEREOF, IN WHICH R1 IS N-BUTYL, ISOBUTYL, CYCLOPENTYL, CYCLOHEXYL, 4-METHYLCYCLOHEXYL, CYCLOHEXENYL OR ENDOETHYLENECLOHEXYL, R2 IS METHYL, METHOXY, CHLORINE, BROMINE OR HYDROGEN, R3 AND R4 ARE EACH HYDROGEN, OR R3 AND R4 MAY TOGETHER FORM AN ADDITIONAL BOND IN WHICH CASE R2 IS CHLORINE, ONLY. THESE COMPOUNDS ARE USEFUL IN THE ORAL TREATMENT OF DIABETES MELLITUS.